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Abstract
Background: Following the development of resistance to anti-malarial mono-therapies, malaria endemic countries
in Africa now use artemisinin-based combination therapy (ACT) as recommended first-line treatment for
uncomplicated malaria. Patients’ adherence to ACT is an important factor to ensure treatment efficacy, as well as to
reduce the likelihood of parasite resistance to these drugs. This study reports adherence to a specific ACT,
artemether-lumefantrine (AL), under conditions of routine clinical practice in Kenya.
Method: The study was undertaken in Garissa and Bunyala districts among outpatients of five government health
facilities. Patients treated with AL were visited at home four days after having been prescribed the drug.
Respondents (patients ≥ 15 years and caregivers of patients < 15 years) were interviewed using a standardized
questionnaire, AL blister packs were physically inspected and the adherence status of patients was then recorded.
Multivariate logistic regression modelling was used to determine predictors of adherence.
Results: Of the 918 patients included in the study, 588 (64.1%) were ‘probably adherent’, 291 (31.7%) were
‘definitely non-adherent’ and 39 (4.2%) were ‘probably non-adherent’. Six factors were found to be significant
predictors of adherence: patient knowledge of the ACT dosing regimen (odds ratio (OR) = 1.76; 95% CI = 1.32-
2.35), patient age (OR = 1.65; 95% CI = 1.02-1.85), respondent age (OR = 1.37; 95% CI = 1.10-2.48), whether a
respondent had seen AL before (OR = 1.46; 95% CI = 1.08-1.98), whether a patient had reported dislikes to AL (OR
= 0.62 95% CI = 0.47-0.82) and whether a respondent had waited more than 24 hours to seek treatment (OR =
0.73; 95% CI = 0.54-0.99).
Conclusion: Overall, adherence to AL was found to be low in both Garissa and Bunyala districts, with patient
knowledge of the AL dosing regimen found to be the strongest predictor of adherence. Interventions aimed at
increasing community awareness of the AL dosing regimen, use of child friendly formulations and improving
health workers’ prescribing practices are likely to ensure higher adherence to AL and eventual treatment success.
Background
Plasmodium falciparum causes approximately 0.5 billion
clinical episodes each year and the majority are borne
by populations living in Africa [1,2]. The last 10 years
has witnessed a rapid scaling-up of malaria prevention
due to massive increases in donor assistance to support
malaria control in Africa [3]. The greatest threat to the
future of malaria control during the early part of this
decade was the rapid and wide-spread emergence of
resistance to widely used mono-therapies, such as chlor-
oquine (CQ) and sulphadoxine/sulphalene-pyrimetha-
mine (SP) [4,5]. However, between 2003 and 2010, all
malaria endemic countries in Africa switched to using
artemisinin-based combination therapy (ACT) as a
recommended first-line treatment for uncomplicated
malaria.
Artemisinin-derived drugs are fast acting anti-malarials
with high clinical efficacies and rapid parasite elimination
profiles that, when combined with other compounds with
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any medium, provided the original work is properly cited.different parasite targets, are likely to reduce the prob-
ability and speed of resistance [6]. However, most ACT
preparations have more complex dosing regimens than
previously used mono-therapies [7]. Recent research has
focussed on factors that influence a patient’s adherence
to the full course of ACT, including dosing complexity,
costs and perceived rapid improvement, and how they
can impact on clinical and pharmacological efficacy
[8-15]. In theory, approaches that reduce patient non-
adherence with ACT should mitigate the risks of resis-
tance emerging in areas of high parasite transmission.
There is a growing need to address the possibilities of
reduced efficacy to artemisinin in Africa following alarm-
ing reports of resistance and treatment failure to both
artemisinin-mefloquine and artemether-lumefantrine (AL)
combinations along the Cambodia-Thailand border and
in Vietnam [16-18]. Given that resistance to SP and CQ
are believed to have originated from similar foci in
South-Eastern Asia [19-21], concerns have been raised
that resistance to ACT may spread to Africa if resistance
is not contained and ACT use in Africa is not regulated
[22,23].
In Kenya, first-line treatment recommendations for
uncomplicated malaria were changed from CQ to SP in
1998, and then from SP to AL in 2004; however this
policy change was not implemented until the second
part of 2006 when AL was distributed to government
and mission public sector facilities, revised national
standard treatment guidelines were changed and front-
line health workers underwent in-service training [24].
However, since 2006 there have been problems asso-
ciated with drug procurement and supply [25], coverage
of health worker training and supervision [26-28] and
clarity on how to prescribe AL [7]. This was an observa-
tional study of patient adherence to AL under standard
conditions of clinical practice in two regions of Kenya.
Methods
Study sites
The study was undertaken in two districts: Bunyala dis-
trict, Western Province, close to Lake Victoria with per-
ennial malaria transmission and community-based
parasite prevalence among children in excess of 40%
[29], and Garissa district, North-Eastern Province, a
semi-arid region with acutely seasonal malaria transmis-
sion and childhood parasite prevalence of less than 1%
during the dry season [29]. Two government health
facilities were selected in Bunyala district (Budalangi dis-
pensary and Mukhobola health centre), and three dis-
pensaries in Garissa district (G. K. Prison, Utawala and
Young Muslim). Mukhobola had an outpatient, as well
as an inpatient facility, whilst the remaining four had
outpatient facilities only. At outpatient facilities, the
clinical officers or community health nurses were
responsible for prescribing and dispensing AL.
Study population
Patients were recruited from selected health facilities
between September and December 2009 in Bunyala, and
between July and August 2010 in Garissa. Inclusion cri-
teria were: testing positive for malaria parasites using
slide microscopy or rapid diagnostic tests, having a
weight of ≥ 5 kg and being more than 5 months of age.
If these patients had reported no other anti-malarial use
during the preceding two weeks, had no signs of com-
plicated malaria or other severe disease, and did not
have another household member participating in the
study, they were recruited until 646 patients had been
enrolled in Budalangi in three age groups (< 5 years, 5-
14 years and ≥ 15 years), and 272 had been enrolled in
G a r i s s ai nt w oa g eg r o u p s( <1 4y e a r sa n d≥ 15 years).
Given the low transmission of malaria during the dry
season in Garissa, the sample size had been reduced to
accommodate for fewer patients attending the health
facilities. Correspondingly,s a m p l es i z ew a sb a s e do na
projected adherence of 70% in Garissa and 60% in Buda-
langi, 10% precision in the point estimate, a 5% type-1
error and an estimated 20% loss to follow-up (EpiInfo
3.5.1, CDC, WHO).
Study procedures
All patients that fulfilled the entry criteria and were pre-
scribed AL were asked to keep their blister packs once
they had completed the medication, and details were
recorded of each patient’s residential address and clinic
card. Patients were not told why their details were being
taken or why they were required to keep their blister
packs, thus ensuring patient adherence was not affected
by knowledge of the survey.
On the fourth day after recruitment, patients were fol-
lowed-up at home, by which time all doses should have
been taken. All respondents, in this case patients aged
15 years or more and caregivers of patients aged less
than 15 years, had the study explained to them in a lan-
guage they were most familiar with, and written
informed consent was obtained. Interviews were con-
ducted by field officers using a structured questionnaire
written in English and translated into KiSomali (Garissa
district), BaLuya (Bunyala district) or KiSwahili where
appropriate (see Additional File 1). The questionnaire
included information on socio-demographic characteris-
tics of the patient/caregiver and of their household
(household size, education level, employment status),
details of information provided by the prescribers at the
health facilities (whether or not they were told how to
take AL correctly), respondent knowledge of the AL
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treatment (whether or not any dislikes or side-effects
were reported). Respondent knowledge regarding the
ACT dosing regimen was assessed by asking respon-
dents directly how AL should be taken, and the number
of correct statements given was totalled. Correct state-
ments included taking the first dose immediately, taking
the second dose after 8 hours, taking the remaining
doses in the morning and evening, taking doses with
milk/fatty foods, and taking all the tablets. Additionally,
blister packs were directly observed and the patient’s
adherence status was then recorded. Patients identified
on the day of follow-up who had not completed the
course were asked why, and were then advised to return
to a health facility for follow up treatment.
Analysis
Open-ended questions were reviewed and grouped into
thematic categories that were coded for data entry.
Results were double entered into EpiInfo 3.5.1 (CDC,
WHO) and all data were analysed in STATA 11.0 (Stata
Corporation, College Station, Texas). Patients who had a
blister pack still containing ACT when interviewed were
considered ‘definitely non-adherent’, and patients were
categorized as ‘probably non-adherent’ if they or their
caregivers claimed the doses were not completed but
did not show a blister pack. ‘Probably adherent’ patients
were those who claimed to have completed all the doses
and could show and empty blister pack, as well as
patients who could not show a blister pack, but claimed
to have taken all the tablets.
To identify predictors related to adherence, data from
the two study sites were combined and chi-square tests
were first performed in a univariate logistic regression
model. Outcomes were grouped by those considered
‘probably adherent’ and those considered either ‘prob-
ably’ or ‘definitely non-adherent’. Factors tested at uni-
variate logistic regression included demographic
information relating to the respondent, patient and head
of household, as well as health-seeking behaviour and
patient acceptance of AL. To increase statistical power
and simplify interpretations, multilevel categorical vari-
ables were collapsed into binary ones. A forward step-
wise selection procedure was performed. Predictors
found to be significant at the P ≤ 0.25 level were entered
into a multivariate logistic regression model with
remaining non-significant predictors introduced one at a
time to detect for additional confounders. These
remained in the model if the OR of other predictors in
the model changed by greater than 20%, though no
additional confounders were found. A backwards step-
wise elimination procedure was performed with a P ≤
0.05 criterion for remaining in the model. All regression
analyses were undertaken adjusting for clustering at
health facility level. Any questionnaires with missing
data were not included in the regression models.
Ethical considerations
Ethical approval for the study was provided by the
Kenya Medical Research Institute/National Ethical
Review Committee (protocol number 1742).
Results
Description of population
A total of 893 patients in Bunyala district were enrolled;
87 (9.7%) were excluded from interview because mem-
bers of their household had already been interviewed, 80
(9.0%) refused participation and 80 (9.0%) were lost to
subsequent follow-up. Of the remaining 646 patients,
approximately equivalent recruitment was obtained
across the three age groups and gender. A total of 351
patients were enrolled in Garissa. Of these, 43 (12.3%)
did not meet the inclusion criteria as a member of their
household had already been interviewed, two (0.6%)
refused to participate and 34 (9.7%) were lost to follow-
up and thus were not included in the final analysis.
Approximately equivalent age group recruitment was
observed in the final sample of 272 patients, though
these groups were significantly different regarding sex
distribution. The characteristics of the recruited study
populations in both districts are shown in Table 1.
Adherence - Bunyala and Garissa district
Of the 918 patients treated with AL, 697 (76.1%) retained
and showed a treatment blister pack during the home
visit. Overall, 588 (64.1%) patients claimed to have taken
all tablets and were considered ‘probably adherent’,o f
whom 69.2% (407/588) showed empty blister packs dur-
ing the home visit. A further 291 (31.7%) patients had AL
doses remaining in their blister pack and were therefore
considered ‘definitely non-adherent’. Only 39 (4.3%)
patients reported they had taken their drugs incorrectly
and had not retained their blister packs. These patients
were therefore categorized as ‘probably non-adherent’.
Nearly equal proportions of adherence were observed in
the two study sites (Table 2).
Univariate logistic regression analysis compared 19
predictors of patients who were classified as adherent (n
= 588) versus those that were not adherent (n = 330).
Fourteen predictors with P-value ≤ 0.25 were fitted in a
multivariate logistic regression model: patient age (< 15
and ≥ 15 years); respondent and head of household age
(< 25, 25-50 or > 50 years); respondent education level
(never attended, primary level or secondary level and
above); if the respondent and head of household was
employed; household size (0-5 and ≥ 6); if patient had
waited more than 24 hours to seek treatment; if respon-
dent had taken AL before; if respondent had seen AL
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treatment, patient knowledge (no knowledge of how to
take AL and at least one correct statement) and if the
patient had been given any instructions as to how to
take AL at the health facility. Six variables were signifi-
cantly (P < 0.05) associated with the outcome after
allowing for potential confounders (Table 3). The stron-
gest predictor of adherence concerned patient knowl-
edge of the ACT regimen; if a patient was able to cite at
least one correct instruction as to how to take AL, they
had 1.76 (95% CI = 1.32-2.35) the odds of being fully
adherent than a respondent () that could cite none.
Table 1 Main characteristics of study participants
Bunyala District < 5 5 - 14 ≥ 15 Total
n = 212 n = 213 n = 221 n = 646
Patient sex*
Male 99 (47.1%) 96 (45.1%) 89 (40.3%) 284 (44.2%)
Female 111 (52.9%) 117 (54.9%) 130 (59.4%) 358 (55.8%)
Education of head of household*
Never attended 13 (6.5%) 12 (6.1%) 23 (11.3%) 48 (8.0%)
Primary 130 (65.0%) 97 (49.2%) 95 (46.8%) 322 (53.8%)
Secondary 45 (22.5%) 60 (30.5%) 53 (26.1%) 158 (26.4%)
Above secondary 10 (5.0%) 28 (14.2%) 32 (15.8%) 70 (11.7%)
N/A 2 (1.0%) 0 (0.0%) 0 (0.0%) 2 (0.3%)
Employment of head of household*
Agriculture 81 (40.3%) 83 (41.9%) 87 (43.1%) 251 (41.8%)
Trade/private business 38 (18.9%) 36 (18.2%) 41 (20.3%) 115 (19.1%)
Fishing 54 (26.9%) 34 (17.2%) 25 (12.4%) 113 (18.8%)
School 1 (0.5%) 1 (0.5%) 0 (0.0%) 8 (4.0%)
Unemployed 9 (4.5%) 11 (5.6%) 2 (1.0%) 22 (3.7%)
Household size*
0-5 124 (58.5%) 80 (38.1%) 116 (57.4%) 320 (51.3%)
≥ 6 88 (41.5%) 130 (61.9%) 86 (42.6%) 304 (48.7%)
Children < 5 years in household*
≤ 1 65 (30.7%) 139 (66.2%) 146 (72. 3%) 350 (56.1%)
> 1 147 (69.3%) 71 (33.8%) 56 (27.7%) 274 (43.9%)
Garissa District < 15 ≥ 15 Total
n = 136 n = 136 n = 272
Patient sex
Male 71 (52.2%) 41 (30.2%) 112 (41.2%)
Female 65 (47.8%) 95 (69.9%) 160 (58.8%)
Education of head of household
Never attended 94 (69.1%) 84 (61.8%) 178 (65.4%)
Primary 16 (11.8%) 22 (16.2%) 38 (14.0%)
Secondary and above 26 (19.1%) 30 (22.1%) 56 (20.6%)
Employment of head of household
Farming/other 39 (30.2%) 51 (37.5%) 90 (33.1%)
Housewife 18 (13.2%) 7 (5.2%) 25 (9.2%)
Own business 35 (25.7%) 39 (28.7%) 74 (27.2%)
Retired/unemployed 43 (31.6%) 38 (27.9%) 81 (29.8%)
In school 1 (0.7%) 1 (0.7%) 2 (0.7%)
Household size*
0-5 36 (26.5%) 47 (34.8%) 83 (30.6%)
≥ 6 100 (73.5%) 88 (65.2%) 188 (69.3%)
Children < 5 years in household*
≤ 1 57 (41.9%) 80 (59.3%) 137 (50.6%)
> 1 79 (58.1%) 55 (40.7%) 134 (49.5%)
*Not all households provided complete demographic information in the survey
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was aged between 25-50 years as opposed to less than
25 years (odds ratio (OR) = 1.65, 95% CI = 1.10-2.48);
whether a patient was aged 15 years or more as opposed
to less than 15 (OR = 1.37, 95% CI = 1.02-1.85);
whether a respondent had seen the drug before or not
(OR = 1.46, 95% CI = 1.08-1.98); whether a patient had
reported dislikes to medication or not (OR = 0.62, 95%
CI = 0.47-0.82) and if a respondent had waited more
than 24 hours to seek treatment as opposed to seeking
treatment in ≤ 24 hours after becoming symptomatic
(OR = 0.73, 95% CI = 0.54-0.99).
Discussion
Adherence to AL is of particular importance given the
large scale-up of ACTs in sub-Saharan Africa [30]. This
study has revealed that patient adherence to AL, four
years after the national roll-out of the new treatment
policy in Kenya, was 64%. Overall, adherence levels were
f o u n dt ob ec o n s i d e r a b l yl o w e ri nt h i ss t u d yt h a ni n
other similar studies. Only 64% of patients from Bunyala
and Garissa district were ‘probably adherent’ and had
taken the full six-dose regimen, whereas 98% of patients
in a study in Tanzania were reported to be ‘probably
adherent’ one year after AL was adopted as a first-line
treatment for uncomplicated malaria [11], and 90%
adherence to the same drug was reported in Uganda [9].
A potential reason for the discrepancies in adherence
levels between these studies is due to the operational
conditions under which they were conducted; in Tanza-
nia and Uganda, health workers had been trained in the
use of anti-malarials prior to the study, the first AL
dose was administered at facilities under the direct
observation, and adequate counselling on how to take
AL was systematically provided [31]. However, as this
study was carried out without the involvement of study
teams in the treatment of patients, it may be a more
accurate reflection of true adherence to AL under nor-
mal, real-life conditions. Similarly, Beer et al [31] and
Depoortere et al [32] investigated adherence under rou-
tine conditions and found 77% and 39% adherence,
respectively, with both studies attributing poor adher-
ence to weaknesses at prescription level. Likewise, this
study highlights poor patient knowledge of the AL dos-
ing regimen as a reason for low adherence, a factor that
can also be improved with better prescribing practice at
health facilities.
Correct knowledge of the AL dosing regimen is criti-
cally important as non-adherence can lead to treat-
ment failure, recrudescence and increase the risk of
malaria parasite resistance [18]. For optimal results,
Table 3 Bivariate (crude) and multivariate (adjusted) model of association between adherence and exposure variables
Variable No. of patients Adherent Crude OR P Value Adjusted OR P Value
n = 918 n = 588 (%) (95% CI) (95% CI)
Patient age
< 15 561 346 (61.7) 1.0 (ref)
≥ 15 357 242 (67.8) 1.31 (0.96-1.78) 0.087 1.37 (1.02-1.85) 0.038
Respondent age
13-24 284 157 (55.3) 1.0 (ref)
25-50 546 376 (68.9) 1.79 (1.42-2.25) < 0.0001 1.30 (1.10-2.48) 0.016
≥ 51 80 49 (61.3) 1.28 (0.84-1.95) 0.256 1.58 (0.63-2.45) 0.533
Days waited to attend health facility
≤ 1 453 310 (68.4) 1.0 (ref)
> 1 465 278 (59.8) 0.69 (0.55-0.85) 0.001 0.73 (0.54-0.99) 0.046
Respondent seen drug before
No 123 73 (59.3) 1.0 (ref)
Yes 791 513 (64.9) 1.26 (0.87-1.85) 0.225 1.46 (1.08-1.98) 0.014
Dislikes
No 811 533 (65.7) 1.0 (ref)
Yes 107 55 (51.4) 0.55 (0.35-0.87) 0.011 0.62 (0.47-0.82) 0.001
Patient number of correct statements
No correct statements 170 87 (51.2) 1.0 (ref)
At least one correct statement 748 501 (67.0) 1.94 (1.49-2.51) < 0.0001 1.76 (1.32-2.35) < 0.0001
Table 2 Patients’ adherence to artemether-lumefantrine
in study districts
Bunyala Garissa
n = 646 n = 272
Probably adherent 412 (63.8%) 176 (64.7%)
Definitely non-adherent 207 (32.0%) 84 (30.9%)
Probably non-adherent 27 (4.2%) 12 (4.4%)
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ensure high levels of artemether in the blood, followed
by the second dose after a strict 8-hour interval to
maintain a high level of the drug in the bloodstream
[9,33]. After introducing health worker counselling of
patients in Nigeria and Tanzania, adherence was found
to reach 73.3% and 75.0%, respectively [34,35]; this
indicates that improving prescriber practice and coun-
selling of patients during health facility visits is likely
to increase patient knowledge and improve adherence.
This study also found a significant association between
patient knowledge and adherence; patients who could
give at least one correct answer as to how to take AL
had 1.76 the odds of taking all the tablets. The issue of
education on the subject of the AL dosing regimen is a
major predictor of adherence and focus on improving
instructions given to patients and caregivers at health
facilities, and thereby increasing caregivers’ and
patients’ understanding of the treatment, could help to
improve treatment with AL.
The relative bioavailability of artemether is known to
increase more than two-fold, and that of lumefantrine
sixteen-fold, when AL is taken after a high-fat meal,
compared to fasted conditions [33]. In this study, only
41.4% of patients receiving AL knew to take this with
food or milk. Encouraging health workers to correctly
educate patients to take AL with fatty foods may help
improve the curative efficacy of the treatment and sub-
sequently the confidence of communities using AL.
Respondent age was a significant predictor for full
adherence to AL in this study. A similar association was
reported in Senegal, where it was concluded that older
caregivers spent more time at home, could better attend
to younger patients and knew more with regards to
administering ACT [14]. It is likely that older respon-
dents may have had prior experience administering or
taking AL, which is supported by evidence from this
study that indicates respondents who had seen AL
before, had the odds 1.46 of adhering fully.
Patient age was also an important predictor of adher-
ence; children aged 15 years or over, and adults, who
receive AL are more likely to be adherent than children
aged less than 15. This implies that younger children
may need more help remembering to take anti-malarials
and ensuring that all doses are completed. Conversely,
in Senegal, children aged 8 to 10 were three times more
likely to be non-adherent than children 2 to 4 years. In
this case, children aged 8 to 10 were reported to have
more responsibilities and be less supervised by care-
givers, and were more likely to either forget to take
doses, or stop taking doses as soon as they felt better
[13]. Encouraging health workers to reinforce the
importance of the caregiver’s role and ensure their
understanding of administering treatment may help to
improve adherence in children.
This study indicates that early treatment seeking for
AL was positively associated with improved adherence;
patients who took more than 24 hours to seek treatment
at a health facility were 27% less likely to adhere fully.
Late treatment seeking for malaria is associated with
increased mortality as most deaths occur within 24-48
hours of onset of symptoms [36]. The importance of
encouraging caregivers and patients to seek early diag-
nosis and effective treatment is vital if malaria mortality
rates are to be successfully reduced. In this study 51% of
malaria patients delayed more than 24 hours before
seeking treatment.
Disadvantages of AL include the large number of
tablets that need to be taken to complete the full course
of therapy. This is further complicated by the fact that
the first two doses of AL need to be taken 8 hours
apart, and the remaining doses taken twice a day in the
morning and evening. In this study, patients reporting
dislikes to AL, such as taste and smell, were less likely
to be fully adherent (OR = 0.62). Increasing the accept-
ability of AL is very important in Kenya, where it was
found 36% of people are non-compliant. Other studies
have focussed on addressing dislikes to AL in children,
with a recent study in collaboration with Novartis
® eval-
uating a novel dispersible tablet of Coartem
® in different
flavours. These are specifically designed with clear
instructions to promote adherence and the sweeter fla-
vour encourages children to take their medication [37].
Increased use of dispersible AL may reduce difficulties
administering medication to children, and therefore
positively improve adherence in the future. Manufac-
turers of other formulations of ACT have addressed
acceptability and adherence issues by significantly redu-
cing the daily number of tablets required [38].
Given that the reported associations between predic-
tors and adherence to AL in this study are weak (OR <
2), this may also indicate that the true causes of adher-
ence were not identified and that further investigation
using different experimental designs need to be explored.
This study has been valuable in identifying a method to
quantitatively determine adherence. However, to fully
understand the factors that cause adherence to AL,
further qualitative studies should be conducted using
methods such as focus group discussions and monitoring
of consultations at health facilities. Patient knowledge of
the dosing regimen has been shown to be associated to
adherence, however the role of patient knowledge of the
AL dosing regimen, patient awareness of malaria and
adherence to anti-malarials should be investigated further
to determine if they are true predictors of adherence,
both at an individual and a community level.
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Overall, adherence to AL in Garissa and Bunyala dis-
tricts was low. This study has highlighted that improv-
ing patient knowledge regarding the AL dosing regimen
may improve the likelihood of patients adhering fully to
AL. Focusing on health worker training and prescribing
practice is essential; materials such as posters and video-
tapes have been seen to improve health worker perfor-
mance [32,39] and the distribution of treatment
guidelines and posters are a good short-term solution.
Targeted information, education and communication
activities at the community level may help to increase
awareness of the AL treatment regimen and its uptake,
and reduce the risk of contributing to the development
of parasite resistance. Individuals should be encouraged
to seek health care as soon as possible within 24 hours
of becoming symptomatic. This may reduce the risk of
severe malaria infection and mortality and also improve
adherence to medication.
Additional material
Additional file 1: ACT adherence survey: consent form and
questionnaire. The questionnaire and consent form used for the ACT
adherence surveys to interview patients who had received ACT from a
health centre four days earlier.
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